Neratinib for HER2-positive breast cancer with an overlooked option

• Principais autores: Liting Guo (Autor), Weiwei Shao (Autor), Chenfei Zhou (Autor), Hui Yang (Autor), Liu Yang (Autor), Qu Cai (Autor), Junqing Wang (Autor), Yan Shi (Autor), Lei Huang (Autor), Jun Zhang (Autor)
• Formato: Livro
• Publicado em: BMC, 2023-10-01T00:00:00Z.
• Assuntos: article
• Acesso em linha: Connect to this object online.

Abstract Positive human epidermal growth factor receptor 2 (HER2) expression is associated with an increased risk of metastases especially those to the brain in patients with advanced breast cancer (BC). Neratinib as a tyrosine kinase inhibitor can prevent the transduction of HER1, HER2 and HER4 sig...